Insights into Doublet Therapy and Clinical Trial Takeaways for Metastatic Prostate Cancer Treatment : Episode 7
Opinion
Video
Insights From ARANOTE and Clinical Practice
Author(s):
Key Takeaways
- The ARANOTE trial enables personalized cancer treatment, allowing oncologists to tailor therapy based on individual patient needs and clinical situations.
- Flexibility in the trial design accommodates varying patient profiles, optimizing treatment outcomes and enhancing therapeutic decision-making.
Fred Saad, CQ, MD, FRCS, FCAHS, discusses how the ARANOTE trial results support using darolutamide plus androgen deprivation therapy in a broad range of patients with metastatic hormone-sensitive prostate cancer, offering flexibility in treatment choices by providing an effective non-chemotherapy option that can be tailored to individual patient needs and preferences.
Video Player is loading.
Video Content above is prompted by the following:
- Which patients and clinical situations would this approach be best suited for? How does the ARANOTE trial provide flexibility to the physician and the patient?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
Ongoing Investigations: Expanding the Role of Cretostimogene in NMIBC Care
Diving Deeper: Discussing Results From Cohort C in the BOND-003 Trial
Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
Post-RP incontinence: Low procedure rates examined
Overcoming Challenges for Wider Adoption of TLX250
The Impact of Comorbidities, Adherence, and Access on mCRPC Treatment Decisions
Formulation Matters: Tailoring Abiraterone Dosing for Optimal Absorption and Tolerability
Related Content
